Prostate-specific membrane antigen (PSMA) ligand

Abstract

The present invention generally relates to radiopharmaceuticals, and to their use as tracers, imaging agents in nuclear medicine, and for the treatment of various disease states of PSMA-expressing cancers, particularly prostate cancer and its metastases. In particular, the present invention relates to a PSMA-binding ligand or a pharmaceutically acceptable salt or solvate thereof and the use of said PSMA-binding ligand, wherein the PSMA-binding ligand comprises at least one neutral amino acid X, optionally N-alkylated i and at least one linker L comprising AQ a PSMA-binding motif Q and a chelator residue A linked via

Description

Technical Field

[0001] The present invention generally relates to radiopharmaceuticals and their use as tracers, imaging agents in nuclear medicine, and for the treatment of various disease states of PSMA-expressing cancers, particularly prostate cancer and its metastases.

Background Art

[0002] Prostate cancer (PCa) is a major cancer in people in the US and Europe. It is estimated that at least 1 to 2 million men in the Western Hemisphere suffer from prostate cancer, and the disease is estimated to affect 1 in 6 men between the ages of 55 and 85. There are over 300,000 new cases of prostate cancer diagnosed each year in the USA. The mortality rate from the disease is second only to lung cancer. Currently, imaging methods using high-resolution anatomy, such as computed tomography (CT), magnetic resonance (MR) imaging, and ultrasound, are superior for the clinical imaging of prostate cancer. Currently, an estimated $2 billion per year is spent worldwide on surgical, radiation, drug, and minimally invasive treatments for prostate cancer. For the treatment of localized prostate cancer, radical prostatectomy with lymph node dissection is an established curative strategy. However, accurate localization and contouring of the tumor margins and metastases remain difficult. Currently, there is no effective treatment for recurrent, metastatic, androgen-independent prostate cancer.

[0003] Tumors are well known to be able to express unique proteins associated with their malignant phenotypes or to overexpress normal constitutive proteins in greater numbers than normal cells. The expression of different proteins on the surface of tumor cells provides opportunities to diagnose and characterize the disease by exploring the phenotypic identity as well as the biochemical composition and activity of the tumor. Radiomolecules that selectively bind to specific tumor cell surface proteins offer an attractive route for imaging and treating tumors under non-invasive conditions. A promising new series of low molecular weight imaging agents target the prostate-specific membrane antigen (PSMA) (Mease R.C. et al., Clin Cancer Res. 2008, 14, 3036 - 3043; Foss, C.A. et al., Clin Cancer Res 2005, 11, 4022 - 4028; Pomper, M.G. et al., Mol Imaging 2002, 1, 96 - 101; Zhou, J. et al., Nat Rev Drug Discov 2005, 4, 015 - 1026; WO 2013 / 022797).

[0004] Radiolabeled choline analogs 18 F]Fluorodihydrotestosterone( 18 F]FDHT), anti-1-amino-3- 18 F]Fluorocyclobutyl-1-carboxylic acid (anti 18 F]F-FACBC, 11 C]Acetate and 1-(2-deoxy-2- 18 F]Fluoro-L-arabinofuranosyl)-5-methyluracil(- 18A variety of experimental low molecular weight PCa imaging agents containing [[F]]FMAU) are currently being clinically pursued (Scher, B. et al., Eur J Nucl Med Mol Imaging 2007, 34, 45 - 53; Rinnab, L et al., BJU Int 2007, 100, 786, 793; Reske, S.N. et al., J Nucl Med 2006, 47, 1249 - 1254; Zophel, K., Kotzerke, J. Eur J Nucl Med Mol Imaging 2004, 31, 756 - 759; Vees, H. et al., BJU Int 2007, 99, 1415 - 1420; Larson, S. M. et al., J Nucl Med 2004, 45, 366 - 373; Schuster, D.M. et al., J Nucl Med 2007, 48, 56 - 63; Tehrani, O.S. et al., J Nucl Med 2007, 48, 1436 - 1441). Each acts by a different mechanism and has certain advantages, such as 11 low urinary excretion for [[C]]choline and disadvantages, such as a short physical half - life of the positron - emitting radionuclide.

[0005] PSMA is a transmembrane 750-amino acid type II glycoprotein that has abundant and restricted expression on the surface of PCa, particularly in androgen-independent advanced and metastatic disease (Schulke, N. et al., Proc Natl Acad Sci U S A 2003, 100, 12590-12595). The latter is important because almost all PCa becomes androgen-independent over time. PSMA has the criteria of a promising target for therapy (Schulke, N. et al., Proc. Natl. Acad. Sci. U S A 2003, 100, 12590-12595). The PSMA gene is located on the short arm of chromosome 11 and functions as both a folate hydrolase and a neuropeptidase. It has a neuropeptidase function equivalent to glutamate carboxypeptidase II (GCPII), termed "brain PSMA", and can modulate glutamatergic transmission by cleaving N-acetylaspartylglutamate (NAAG) into N-acetylaspartate (NAA) and glutamate (Nan, F. et al., J Med Chem 2000, 43, 772-774). There are up to 10 6 PSMA molecules per cancer cell, which further suggests it as an ideal target for imaging and therapy using radionuclide-based techniques (Tasch, J. et al., Crit Rev Immunol 2001, 21, 249-261).

[0006] The radioimmunoconjugate of the anti-PSMA monoclonal antibody (mAb) 7E11, known as PROSTASCINT® scan, is currently used to diagnose prostate cancer metastasis and recurrence. However, this agent tends to produce images that are difficult to interpret (Lange, P.H. PROSTASCINT scan for staging prostate cancer. Urology 2001, 57, 402-406; Haseman, M.K. et al., Cancer Biother Radiopharm 2000, 15, 131-140; Rosenthal, S.A. et al., Tech Urol 2001, 7, 27-37). More recently, monoclonal antibodies that bind to the extracellular domain of PSMA have been developed, radiolabeled, and shown to accumulate in PSMA-positive prostate tumor models in animals. However, diagnostic and tumor detection using monoclonal antibodies are limited by the low permeability of monoclonal antibodies in solid tumors.

[0007] The selective targeting of cancer cells using radiopharmaceuticals for either imaging or therapeutic purposes is difficult. 111 In 90 Y 68 Ga 177 Lu 99m Tc 123 I and 131 I, various radionuclides are known to be useful for radioimaging or cancer radiotherapy. In recent years, some compounds containing glutamate-urea-glutamate (GUG) or glutamate-urea-lysine (GUL) recognition elements linked to radionuclide-ligand conjugates have been shown to exhibit high affinity for PSMA.

[0008] In WO 2015 / 055318, new imaging agents with improved tumor targeting properties and pharmacokinetics are described. These compounds contain a motif that specifically binds to the cell membrane of cancerous cells, and the motif contains prostate-specific membrane antigen (PSMA), which is the glutamate-urea-lysine motif described above. Preferred molecules described in WO 2015 / 055318 further contain a linker that binds to the carboxylic acid group of DOTA via an amide bond as a chelating agent. Some of these compounds have been shown to be promising agents for the specific targeting of prostate tumors. The compounds are 177 labeled with Lu (for therapeutic purposes) or 68 Ga (for diagnostic purposes), enabling visualization and targeting of prostate cancer for radiotherapy purposes.

[0009] However, in the therapeutic use of radiolabeled PSMA inhibitors, organs with physiological PSMA expression have been found to be dose-limiting, thus minimizing the success of treatment. In particular, the high uptake of radiolabeled PSMA inhibitor substances by the adrenal and salivary glands is noteworthy, as this causes significant side effects in the case of therapeutic use. Attempts to improve the uptake of PSMA inhibitors by the kidneys led to the development of PSMA-617 [Benesova, M. et al. (2016) J Med Chem 59, 1761-75], which is already clinically used with 177Lu or 225Ac for the internal radiotherapy of prostate cancer. However, reduction of uptake by the salivary and lacrimal glands has still not been achieved and is still described as decisive and dose-limiting in early clinical work. In a first-in-human study using 225Ac-PSMA-617, two patients with very advanced and terminal disease showed complete remission. In both patients, the PSA value decreased below the limit of detectability. An accompanying diagnostic record using 68Ga-PSMA-11 confirmed complete response.

[0010] As already described above, the strong accumulation of PSMA ligands in non-target tissues, especially the salivary and lacrimal glands, which is described in numerous scientific publications, results in considerable side effects. The salivary and lacrimal glands can be severely and partially irreversibly damaged, especially during alpha therapy using 225Ac. The resulting symptoms of dry mouth, for example, represent a dose-limiting side effect. To solve this problem, an improvement in the tissue specificity of PSMA ligands has been proposed, for example, in WO 2020 / 165420 A1.

Summary of the Invention

Problems to be Solved by the Invention

[0011] Nevertheless, there is still a need for improved PSMA ligands that provide advantageous options for the detection, treatment, and management of PSMA-expressing cancers, especially prostate cancer, and preferably exhibit fewer side effects and / or improved specificity in labeling and / or radiotherapy.

Means for Solving the Problems

[0012] The solution to the above object is achieved by providing embodiments characterized in the claims.

[0013] The inventors have found novel PSMA-binding ligands that are useful and advantageous radiopharmaceuticals and can be used as tracers and imaging agents in nuclear medicine and for the treatment of various disease states of PSMA-expressing cancers, especially prostate cancer.

[0014] These PSMA-binding ligands are described in more detail below.

[0015] In particular, the invention relates to at least one linker L comprising at least one neutral amino acid X, optionally N-alkylated 1 AQA PSMA-binding ligand or a pharmaceutically acceptable salt or solvate thereof, comprising a PSMA-binding motif Q and a chelator residue A linked via, X 1 is preferably selected from the group consisting of Gly, Ala, βAla, Phe, aminohexanoic acid (Ahx = -NH-(CH 2 2) 5 -C(=O)-), and an amino acid containing at least one -(CH2-CH2-O)- group between the N-terminus and the C-terminus, or X 1 is Tyr, more preferably, X 1 is selected from the group consisting of Gly, Ala, βAla, Phe, and an amino acid residue having the structure -NH-CH 2 -CH 2 -O-(CH 2 -CH 2 -O) x1 -(CH2) y1 -C(=O)- (wherein x1 is an integer in the range of 0 to 15 and y1 is 1 or 2), or X 1 is Tyr, relating to a PSMA-binding ligand or a pharmaceutically acceptable salt or solvate thereof.

[0016] In particular, the present invention relates to a PSMA-binding ligand having the structure (I) A-L AQ -Q (I) wherein the PSMA-binding motif Q and the chelator residue A are linked via at least one linker L 1 containing at least one neutral amino acid X AQ relates to a PSMA-binding ligand.

[0017] Furthermore, the present invention relates to (a) a radionuclide, and (b) a PSMA-binding ligand or a pharmaceutically acceptable salt or solvate thereof as described above or below relates to a complex containing.

[0018] Furthermore, the present invention relates to a pharmaceutical composition comprising a PSMA-binding ligand as described above or below, or a pharmaceutically acceptable salt or solvate thereof as described above or below, or a complex as described above or below.

[0019] Furthermore, the present invention relates to a PSMA-binding ligand as described above or below, or a pharmaceutically acceptable salt or solvate thereof as described above or below, or a complex as described above or below, or a pharmaceutical composition as described above or below, for use in the treatment or prevention of PSMA-expressing cancer, particularly prostate cancer, and / or its metastasis. BRIEF DESCRIPTION OF THE DRAWINGS

[0020]

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Figure 9

Figure 10

Figure 11

Figure 12

Figure 13

Figure 14

Figure 15

Figure 16

Figure 17

Figure 18

Figure 19

Figure 20

Figure 21

Figure 22

Figure 23

Figure 24

Figure 25

Mode for Carrying Out the Invention

[0021] When used hereinafter, the terms "have", "comprise", "include" or any grammatical variations thereof are used non-exclusively. Thus, these terms can refer to both situations where no additional features are present in the entity described in the context other than the features introduced by these terms, and situations where one or more additional features are present. By way of example, the expressions "A has B", "A comprises B" and "A includes B" can refer to both situations where no other elements are present in A other than B (i.e., the situation where A consists solely and exclusively of B), and situations where one or more additional elements such as element C, elements C and D, or further elements are present in entity A other than B. Moreover, as will be understood by those skilled in the art, the expressions "comprising a" and "comprising an" preferably refer to "comprising one or more", i.e., are equivalent to "comprising at least one".

[0022] Furthermore, when used hereinafter, the terms "preferably", "more preferably", "most preferably", "in particular", "more specifically", "specifically", "even more specifically" or similar terms are used with optional features without restricting further possibilities. Thus, the features introduced by these terms are optional features and are never intended to limit the scope of the claims. The present invention can be implemented, as will be recognized by those skilled in the art, by using alternative features. Similarly, features introduced by "in one embodiment" or similar expressions are optional features and are not intended to impose any limitation with respect to further embodiments of the present invention, with respect to the scope of the present invention, and with respect to the possibility of combining features introduced in this way with other optional or non-optional features of the present invention.

[0023] As used herein, the term "standard conditions" refers to IUPAC standard ambient temperature and pressure (SATP) conditions, i.e., preferably a temperature of 25 °C and an absolute pressure of 100 kPa, unless otherwise specified. Preferably, under standard conditions, pH 7 is included. Further, unless otherwise indicated, the term "about" refers to the indicated value with the technical accuracy generally acceptable in the relevant art, preferably ±20% of the indicated value, more preferably ±10%, and most preferably ±5%. Further, the term "essentially" indicates that there is no deviation having an impact on the indicated result or use, i.e., the possible deviation does not cause a deviation of more than ±20%, more preferably ±10%, and most preferably ±5% of the indicated result. Thus, "consisting essentially of" means excluding other components, including substances present as impurities, inevitable substances resulting from the process used to provide the components, and components added for purposes other than achieving the technical effects of the present invention, while including the specified components. For example, a composition defined using the phrase "consisting essentially of" includes any known acceptable additives, excipients, diluents, carriers, etc. Preferably, a composition consisting essentially of a set of components contains less than 5% by weight, more preferably less than 3% by weight, still more preferably less than 1%, and most preferably less than 0.1% by weight of unspecified components.

[0024] PSMA binding motif The PSMA binding motif Q preferably has the structure

[0025] [Chemical formula] (wherein R 1 is H or -CH 3 , preferably H, and R 2 , R 3 and R 4 are independently of each other -CO 2 H, -SO 2 H, -SO 3 H, -OSO 3 H, -PO 2 H, -PO3 H and -OPO 3 H 2 selected from the group consisting of) has. More preferably, R 2 , R 3 and R 4 are CO 2 H. In particular, R1 is H, and R 2 , R 3 and R 4 are CO 2 H. The wavy line indicates the connection site to the linker L AQ .

[0026] Chelating agent residue A A is a chelating agent residue derived from a chelating agent selected from the group consisting of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (=DOTA), N,N''-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N''-diacetic acid, 1,4,7-triazacyclononane-1,4,7-triacetic acid (=NOTA), 2-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl)pentanedioic acid (NODAGA), 2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1-yl)pentanedioic acid (DOTAGA), 1,4,7-triazacyclononanephosphonic acid (TRAP), 1,4,7-triazacyclononanephosphonic acid (TRAP), 1,4,7-triazacyclononane-1-[methyl(2-carboxyethyl)phosphonic acid]-4,7-bis[methyl(2-hydroxymethyl)phosphonic acid] (NOPO), 3,6,9,15-tetraazabicyclo[9.3.1]pentadec-1(15),11,13-triene-3,6,9-triacetic acid (=PCTA), N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxysuccinamide (DFO), diethylenetriaminepentaacetic acid (DTPA), Trans-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-DTPA), 1-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid (oxo-Do3A), p-isothiocyanatobenzyl-DTPA (SCN-Bz-DTPA), 1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M), 2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B), and 1-(2)-methyl-4-isocyanatobenzyl-DTPA (MX-DTPA).

[0027] The term "chelating agent residue" and typically the term "chelating agent residue derived from a chelating agent selected from the group" as described above means that the chelating agent described above and thus typically the chelating agent defined in the "group" is linked to the remainder of the PSMA binding ligand, preferably via a suitable functional group to linker L AQ is shown to mean that it is linked.

[0028] More preferably, the chelating agent defined in the "group" is linked to the N-terminus of L AQ via the original carboxylic acid group of the chelating agent, thereby forming an amide bond between the chelating agent and L AQ .

[0029] Preferably, A is a group consisting of the following

[0030]

Chemical formula

[0031] Most preferably, A has the structure

[0032]

Chemical formula

[0033] Linker L AQ Preferably, linker L AQ is, in addition to at least one, optionally N-alkylated, neutral amino acid X 1 , preferably the group (X 1 ) n1 (wherein X1 is an optionally N-alkylated, neutral amino acid X 1 and n1 ranges from 2 to 25), and in addition, at least one amino acid building block AS a and / or at least one amino acid building block AS B, preferably at least one amino acid building block AS a and at least one amino acid building block AS B is included.

[0034] Amino acid building block AS a Amino acid building block AS a has, in particular, the structure

[0035] [Chemical formula] (wherein Q 1 is selected from the group consisting of alkylaryl, arylalkyl, aryl, alkylheteroaryl, heteroarylalkyl and heteroaryl). has.

[0036] The term "aryl", when used in the context of the present invention, means an optionally substituted 5- and 6-membered aromatic ring, as well as a substituted or unsubstituted polycyclic aromatic group (aryl group), for example, a tricyclic or bicyclic aryl group. Optionally substituted phenyl or naphthyl groups may be mentioned as examples. The polycyclic aromatic group may also contain non-aromatic rings.

[0037] The term "alkylaryl", when used in the context of the present invention, refers to an aryl group (alkyl-aryl-) in which at least one proton has been replaced by an alkyl group.

[0038] The term "arylalkyl", when used in the context of the present invention, refers to an aryl group (aryl-alkyl-) linked via an alkyl group.

[0039] As used in the context of the present invention, the term "heteroaryl" means an optionally substituted 5- or 6-membered aromatic ring containing one or more, for example 1 to 4, for example 1, 2, 3, or 4 heteroatoms in the ring system, and a substituted or unsubstituted polycyclic aromatic group, such as a tricyclic or bicyclic aryl group. When two or more heteroatoms are present in the ring system, at least two of the heteroatoms present may be the same or different. Suitable heteroaryl groups are known to those skilled in the art. The following heteroaryl residues may be described as non-limiting examples: benzodioxolyl, pyrrolyl, furanyl, thiophenyl, thiazolyl, isothiazolyl, imidazolyl, triazolyl, tetrazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrazinyl, pyridazinyl, benzoxazolyl, benzodioxazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, methylenedioxyphenyl, naphthyridinyl, quinolinyl, isoquinolinyl, indolyl, benzofuranyl, purinyl, benzofuranyl, deazapurinyl, pyridazinyl and indolizinyl.

[0040] As used in the context of the present invention, the term "alkylheteroaryl" refers to a heteroaryl group (alkyl-heteroaryl-) in which at least one proton has been replaced by an alkyl group.

[0041] As used in the context of the present invention, the term "heteroarylalkyl" refers to a heteroaryl group (heteroaryl-alkyl-) linked via an alkyl group.

[0042] As used in the context of the present invention, the term "cycloalkyl" means an optionally substituted cyclic alkyl residue, where they may be monocyclic or polycyclic groups. Optionally substituted cyclohexyl may be described as a preferred example of a cycloalkyl residue.

[0043] As used in the context of the present invention, the term "heterocycloalkyl" refers to an optionally substituted cyclic alkyl residue having at least one heteroatom, such as O, N or S, in the ring, where they may be monocyclic or polycyclic groups.

[0044] As used in the context of the present invention, the term "substituted cycloalkyl residue" or "cycloheteroalkyl" means a cycloalkyl residue or cycloheteroalkyl residue in which at least one H is replaced by a suitable substituent.

[0045] Preferably, Q1 comprises a residue selected from the group consisting of naphthyl, phenyl, biphenyl, indolyl, benzothiazolyl, naphthylmethyl, phenylmethyl, biphenylmethyl, indolylmethyl and benzothiazolylmethyl, and more preferably, Q 1 is from the group consisting of:

[0046]

Chemical formula

[0047]

Chemical formula

[0048] Amino acid building block AS b Amino acid building block AS b preferably has structure (b)

[0049]

Chemical formula

[0050] When the term "aryl" is used in the context of the present invention, it refers to optionally substituted 5- and 6-membered aromatic rings, and substituted or unsubstituted polycyclic aromatic groups (aryl groups), such as tricyclic or bicyclic aryl groups (-Ar-). Optionally substituted phenyl or naphthyl groups may be mentioned as examples. The polycyclic aromatic group may also contain a non-aromatic ring or an aryl group in the context of the present invention.

[0051] When the term "alkylaryl" is used in the context of the present invention, it refers to an aryl group (-alkyl-aryl-) in which at least one proton is replaced by an alkyl group and which is linked via the alkyl group to a -CH2- group and via the aryl group to a carbonyl group.

[0052] When the term "arylalkyl" is used in the context of the present invention, it refers to an aryl group (-aryl-alkyl-) which is linked via the alkyl group to a carbonyl group and via the aryl group to a -CH2- group.

[0053] The term "heteroaryl" (-heteroaryl-), when used in the context of this invention, refers to optionally substituted 5- and 6-membered aromatic rings containing one or more, for example 1 to 4, for example 1, 2, 3, or 4 heteroatoms in the ring system, as well as substituted or unsubstituted polycyclic aromatic groups, such as tricyclic or bicyclic aryl groups. When two or more heteroatoms are present in the ring system, at least two of the heteroatoms present may be the same or different. Suitable heteroaryl groups are known to those skilled in the art. The following heteroaryl residues may be described as non-limiting examples: benzodioxolyl, pyrrolyl, furanyl, thiophenyl, thiazolyl, isothiazolyl, imidazolyl, triazolyl, tetrazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrazinyl, pyridazinyl, benzoxazolyl, benzodioxazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, methylenedioxyphenyl, naphthyridinyl, quinolinyl, isoquinolinyl, indolyl, benzofuranyl, purinyl, benzofuranyl, deazapurinyl, pyridazinyl and indolizinyl.

[0054] The term "alkylheteroaryl", when used in the context of this invention, refers to an aryl group (-alkyl-heteroaryl-) in which at least one proton is replaced by an alkyl group and which is linked via the alkyl group to a -CH2- group and via the heteroaryl group to a carbonyl group.

[0055] The term "heteroarylalkyl", when used in the context of this invention, refers to a heteroaryl group (-aryl-alkyl-) which is linked via the alkyl group to a carbonyl group and via the heteroaryl group to a -CH2- group.

[0056] The term "cycloalkyl" (-cycloalkyl-) means, in the context of the present invention, an optionally substituted cyclic alkyl residue, where they may be monocyclic or polycyclic groups. Optionally substituted cyclohexyl may be described as a preferred example of a cycloalkyl residue.

[0057] The term "heterocycloalkyl", when used in this context of the present invention, refers to an optionally substituted cyclic alkyl residue having at least one heteroatom, such as O, N or S, in the ring, where they may be monocyclic or polycyclic groups.

[0058] The term "substituted cycloalkyl residue" or "cycloheteroalkyl", when used in this context of the present invention, means a cycloalkyl residue or cycloheteroalkyl residue in which at least one H has been replaced by a suitable substituent.

[0059] Preferably, Q 2 is an aryl group or a cycloalkyl group, more preferably

[0060]

Chemical formula

[0061]

Chemical formula

[0062] Any stereoisomers of Q 2 are possible and should be understood to be included. Q 2 when

[0063]

Chemical formula

[0064] The PSMA-binding ligands described above or below preferably belong to the group consisting of (Ia), (Ib) and (Ic).

[0065]

Chemical formula

[0066] The PSMA-binding ligands described above or below are more preferably of structure (Ia)

[0067]

Chemical formula

[0068] More preferably, the PSMA binding ligand described above or below has structure (Ia), and Q 1 includes residues selected from the group consisting of naphthyl, phenyl, biphenyl, indolyl, benzothiazolyl, naphthylmethyl, phenylmethyl, biphenylmethyl, indolylmethyl and benzothiazolylmethyl. More preferably, Q 1 is from the group consisting of

[0069]

Chemical formula

[0070]

Chemical formula

[0071] [Chemical formula] and more preferably

[0072] [Chemical formula] is.

[0073] In particular, the present invention is a PSMA-binding ligand as described above and below, wherein the ligand has a structure

[0074] [Chemical formula] (wherein A is a chelating agent residue having a structure

[0075] [Chemical formula] and Q2 is

[0076] [Chemical formula] and more preferably

[0077] [Chemical formula] and q is 1, Q 1 is

[0078] [Chemical formula] and R 3 、R 2 and R 4 are -CO 2 H, and R 1is H, and n1 is preferably in the range of 5 to 25, preferably 3 to 10, X 1 and n1 are as described above) relates to a PSMA-binding ligand having

[0079] a neutral amino acid X1 as described above, at least one linker L AQ contains at least one neutral amino acid. The term "neutral amino acid", when used within the scope of the present invention, includes any amino acid having no net charge at pH 7. The term includes all naturally occurring amino acids and non-naturally occurring amino acids, for example all stereoisomers of these amino acids, such as enantiomers and diastereomers, for example glycine, alanine, valine, isoleucine, phenylalanine, beta-alanine, and non-natural amino acids containing a neutral linker between the N-terminus and the C-terminus, for example at least one -(CH2-CH2-O)- group between the N-terminus and the C-terminus, and N-alkylated, for example N-methylated amino acids, i.e. amino acids containing an alkyl or methyl group attached to the amino group of the amino acid instead of a proton -H, should be understood to be included.

[0080] N-alkylated amino acids include, but are not limited to, N-alkyl-glycine, N-alkyl-alanine, N-alkyl-valine, N-alkyl-isoleucine, N-alkyl-leucine, N-alkyl-methionine, N-alkyl-phenylalanine, N-alkyl-tyrosine or N-alkyl-tryptophan. N-methylated amino acids include, but are not limited to, N-methylated amino acids selected from the group consisting of N-methylglycine, N-methylalanine, N-methylvaline, N-methylisoleucine, N-methylleucine, N-methylphenylalanine.

[0081] When the amino acid is chiral, the amino acid preferably has an L-conformation.

[0082] Preferably, the neutral amino acid X 1 is selected from the group consisting of Gly, Ala, βAla, Phe, aminohexanoic acid (Ahx = -NH-(CH 2 2 5 2 1 2 2 2 2 2 2 2 2 2 x1 2 y1 2

[0083] According to a more preferred embodiment, the amino acid is tyrosine (Tyr), optionally N-alkylated.

[0084] Optionally, the linker L AQ contains at least one amino acid building block AS a which may be present, and at least one amino acid building block AS B which may be present, and in addition to X 1 and in addition to X, further contains additional amino acids X, preferably all additional amino acids X are neutral amino acids.

[0085] According to one preferred embodiment, the linker L AQ contains an amino acid sequence AA of 2 to 25 amino acids, the amino acid X1 is part of the sequence, and preferably all amino acids present in the sequence are neutral amino acids. It should be understood that the sequence AA contains at least one amino acid X1. Preferably, all amino acids X present in the sequence are the same and are X1.

[0086] Linking unit -(X 1 )n 1 Preferably, linker L AQ comprises an amino acid sequence AA containing a building block (X 1 ) n1 (wherein n1 ranges from 1 to 25, for example 2 to 25). Preferably, the amino acid sequence AA consists of the block (X 1 ) n1 (wherein all amino acids X 1 are the same).

[0087] Preferably, X 1 is Gly, Ala, βAla, Phe, aminohexanoic acid (Ahx = -NH-(CH 2 ) 5 -C(=O)-), and the structure -NH-CH 2 -CH 2 -O-(CH 2 -CH 2 -O) x1 -(CH2) y1 -C(=O)-(wherein x1 is an integer in the range of 0 to 15 and y1 is 1 or 2), optionally N-alkylated. When the linker contains two or more groups X 1 , the amino acids may be the same or different, preferably the same. Preferably, X 1 is not N-alkylated.

[0088] According to an alternative, linker L AQ contains at least one optionally present amino acid building block AS a and at least one optionally present amino acid building block AS B , and in addition one amino acid X 1 , and does not contain any further amino acids. In this case, X 1 is preferably -NH-CH 2 -CH 2 -O-(CH 2 -CH 2 -O) x1 -(CH2) y1-C(=O)- (wherein x1 is an integer in the range of 0 to 15, and y1 is 1 or 2) or aminohexanoic acid (Ahx = -NH-(CH 2 ) 5 -C(=O)-).

[0089] Preferably, the linker L AQ is an amino acid sequence AA containing a structural block -(X 1 )n 1 -, where X 1 is a neutral amino acid, more preferably, X 1 is selected from the group consisting of Gly, Ala, βAla, Phe, aminohexanoic acid (Ahx = -NH-(CH 2 ) 5 -C(=O)-), and an amino acid containing at least one -(CH2-CH2-O)- group between the N-terminus and the C-terminus, preferably, more preferably, X 1 is selected from the group consisting of Gly, Ala, βAla, Phe, and an amino acid residue having the structure -NH-CH 2 -CH 2 -O-(CH 2 -CH 2 -O) x1 -(CH2) y1 -C(=O)- (wherein x1 is an integer in the range of 0 to 15, and y1 is 1 or 2). The integer n1 is preferably in the range of 1 to 25, preferably in the range of 1 to 20).

[0090] According to a first preferred embodiment, the linker L AQ contains at least one group X 1 , where X 1 is selected from the group consisting of Gly, Ala, βAla and Phe.

[0091] More preferably, the linker L AQ contains the group (X 1 ) n1 , where X 1is selected from the group consisting of Gly, Ala, βAla and Phe, and n1 ranges from 2 to 20, preferably from 3 to 15, for example 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, more preferably 3, 5, 10 or 15.

[0092] Thus, according to a preferred embodiment, linker L AQ comprises the group (X 1 ) n1 wherein X 1 is selected from the group consisting of Gly, Ala, βAla and Phe, n1 is 3, and more preferably, X 1 is Gly or Ala, and n1 is 3. Thus, in a preferred embodiment, X 1 is Gly, and n1 is 3. In a more preferred embodiment, X 1 is Ala, and n1 is 3.

[0093] Thus, according to a preferred embodiment, linker L AQ comprises the group (X 1 ) n1 wherein X 1 is selected from the group consisting of Gly, Ala, βAla and Phe, n1 is 5, and more preferably, X1 is Ala, and n1 is 5.

[0094] Thus, according to a preferred embodiment, linker L AQ comprises the group (X 1 ) n1 wherein X 1 is selected from the group consisting of Gly, Ala, βAla and Phe, and n1 is 10.

[0095] Thus, according to a preferred embodiment, linker L AQ comprises the group (X 1 ) n1 wherein X 1 is selected from the group consisting of Gly, Ala, βAla and Phe, and n1 is 15.

[0096] According to a further preferred embodiment, linker L AQ comprises at least one group X 1 wherein X 1 is Gly, and more preferably, the PSMA ligand comprises the group (X 1 ), n1 wherein X 1 is Gly, and n1 ranges from 2 to 20, preferably from 3 to 15, for example 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, more preferably 3, 5, 10 or 15, and even more preferably 3.

[0097] According to a further preferred embodiment, linker L AQ comprises at least one group X 1 wherein X 1 is Ala, and more preferably, the PSMA ligand comprises the group (X 1 ), n1 wherein X 1 is Ala, and n1 ranges from 2 to 20, preferably from 3 to 15, for example 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, more preferably 3, 5, 10 or 15, even more preferably 3 or 5, and most preferably 5.

[0098] According to a further preferred embodiment, linker L AQ comprises at least one group X 1 wherein X 1 is βAla, and more preferably, the PSMA ligand comprises the group (X 1 ), n1 wherein X 1 is βAla, and n1 ranges from 2 to 20, preferably from 3 to 15, for example 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, more preferably 3, 5, 10 or 15.

[0099] According to a further preferred embodiment, linker L AQ comprises at least one group X 1 wherein X 1 is Phe, and more preferably, the PSMA ligand comprises the group (X 1 ), n1comprising X 1 is Phe, n1 ranges from 2 to 20, preferably from 3 to 15, such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, more preferably 3, 5, 10 or 15, still more preferably 3 or 5.

[0100] According to a further preferred embodiment, the linker L AQ comprises at least one group X 1 comprising X 1 is Tyr, and more preferably, the PSMA ligand comprises the group (X 1 ) n1 comprising X 1 is Tyr, n1 ranges from 2 to 20, preferably from 3 to 15, such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, more preferably 3, 5, 10 or 15, still more preferably 3 or 5, and most preferably 3.

[0101] According to a second preferred embodiment, the linker L AQ comprises the group (X 1 ) n1 comprising X 1 is the structure -NH-CH 2 -CH 2 -O-(CH 2 -CH 2 -O) x1 -(CH2) y1 -C(=O)-, the integer x1 ranges from 1 to 15, y1 is 1 or 2, and n1 is 1. Preferably, the integer x1 is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15, more preferably 1, 3, 5, 7.

[0102] According to a preferred embodiment, the linker L AQ comprises the group (X1)n1, X 1 is the structure -NH-CH 2 -CH 2 -O-(CH 2 -CH 2 -O) x1 -(CH2) y1-C(=O)-, where the integer x1 ranges from 1 to 15, preferably from 1 to 7, y1 is 1 or 2, and preferably, y1 is 1. In a preferred embodiment, L AQ comprises the group (X1)n1, and X 1 has the structure -NH-CH 2 -CH 2 -O-(CH 2 -CH 2 -O) x1 -(CH2) y1 -C(=O)-, where the integer x1 is 1 and y1 is 1.

[0103] According to a more preferred embodiment, the linker L AQ comprises the group (X 1 ) n1 , and X1 has the structure -NH-CH 2 -CH 2 -O-(CH 2 -CH 2 -O) x1 -(CH2) y1 -C(=O)-, where the integer x1 is 3 and y1 is 2.

[0104] According to a more preferred embodiment, the linker L AQ comprises the group (X 1 ) n1 , and X 1 has the structure -NH-CH 2 -CH 2 -O-(CH 2 -CH 2 -O) x1 -(CH2) y1 -C(=O)-, where the integer x1 is 5 and y1 is 2.

[0105] According to a more preferred embodiment, the linker L AQ comprises the group (X 1 ) n1 , and X 1 has the structure -NH-CH 2 -CH 2 -O-(CH 2 -CH 2 -O) x1 -(CH2)y1 -C(=O)-, where the integer x1 is 7 and y1 is 2.

[0106] According to a third preferred embodiment, the linker L AQ comprises the group (X 1 ), n1 where X 1 is aminohexanoic acid and n1 is preferably from 1 to 20, preferably from 1 to 15, more preferably from 1 to 4, for example 1, 2, 3 or 4.

[0107] According to a preferred embodiment, the linker L AQ comprises the group (X 1 ), n1 where X 1 is aminohexanoic acid and n1 is 1.

[0108] According to a more preferred embodiment, the linker L AQ comprises the group (X 1 ), n1 where X1 is aminohexanoic acid and n1 is 2.

[0109] According to a more preferred embodiment, the linker L AQ comprises the group (X 1 ), n1 where X 1 is aminohexanoic acid and n1 is 3.

[0110] According to a more preferred embodiment, the linker L AQ comprises the group (X 1 ), n1 where X 1 is aminohexanoic acid and n1 is 4.

[0111] By way of example, a particularly preferred PSMA-binding ligand of the present invention is shown in Table 1:

[0112] [Table 1] TIFF2025516759000023.tif234169TIFF2025516759000024.tif73169

[0113] In particular, the PSMA-binding ligand has a structure as shown in FIG. 1, FIG. 2, FIG. 3, FIG. 4, FIG. 5, FIG. 6, FIG. 7, FIG. 8, FIG. 9, FIG. 10, FIG. 11, FIG. 12, FIG. 13, FIG. 14, FIG. 15, FIG. 16, FIG. 17, FIG. 18, FIG. 19, FIG. 20, FIG. 21 or FIG. 22, and preferably, all chiral amino acids (X1) are present in the L configuration.

[0114] In a preferred embodiment, the PSMA-binding ligand has a structure as shown in FIG. 1, FIG. 2, FIG. 5, FIG. 6, FIG. 13, FIG. 14, FIG. 15, FIG. 16, FIG. 17, FIG. 18, FIG. 19, FIG. 20, FIG. 21 or FIG. 22.

[0115] In certain preferred embodiments, the PSMA-binding ligand has a structure as shown in FIG. 1, FIG. 5, FIG. 6, FIG. 13, FIG. 14, FIG. 15, FIG. 16, FIG. 17, FIG. 18, FIG. 19, FIG. 20, FIG. 21 or FIG. 22, and more preferably, the PSMA-binding ligand has a structure as shown in FIG. 1, FIG. 5, FIG. 6, FIG. 15, FIG. 16, FIG. 17, FIG. 18, FIG. 19, FIG. 20, FIG. 21 or FIG. 22.

[0116] As described above, the present invention relates to (a) a radionuclide, and (b) a PSMA-binding ligand as described above or below or a pharmaceutically acceptable salt or solvate thereof and relates also to a complex comprising the same.

[0117] Typical pharmaceutically acceptable salts include those prepared by reacting the PSMA binding ligand of the present invention with a pharmaceutically acceptable mineral acid or organic acid or organic or inorganic base. Such salts are known as acid addition salts and base addition salts. Acids commonly used to form acid addition salts include inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, etc., and organic acids such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, etc. Examples of such pharmaceutically acceptable salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, hydrochloride, dihydrochloride, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, hydroxybenzoate, methoxybenzoate, phthalate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, gamma-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, etc. Preferred pharmaceutically acceptable acid addition salts are those formed from mineral acids such as hydrochloric acid and hydrobromic acid, and those formed from organic acids such as maleic acid and methanesulfonic acid. The salts of amine groups can also include quaternary ammonium salts in which the amino nitrogen has an appropriate organic group such as an alkyl, alkenyl, alkynyl, or aralkyl moiety. Base addition salts include those derived from inorganic bases such as ammonium or hydroxides, carbonates, bicarbonates of alkali metals or alkaline earth metals, etc.Such bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate and the like. Potassium salt and sodium salt forms are particularly preferred. The specific counterions that form part of any salt of this invention are generally recognized as not being of critical nature so long as the salt is pharmaceutically acceptable as a whole and the counterions do not impart undesired qualities to the salt as a whole.

[0118] The term "pharmaceutically acceptable solvate" also encompasses suitable solvates of the PSMA-binding ligands of the invention, where the PSMA-binding ligand combines with a solvent such as water, methanol, ethanol, DMSO, acetonitrile or mixtures thereof to form suitable solvates such as the corresponding hydrate, methanolate, ethanolate, DMSO solvate or acetonitrilate.

[0119] Radionuclide Depending on whether the PSMA-binding ligand of the invention is to be used as a radioimaging agent or a radiopharmaceutical, different radionuclides are complexed to the chelating agent.

[0120] The complexes of the invention can contain one or more radionuclides, preferably one radionuclide. These radionuclides are preferably suitable for use as radioimaging agents or as therapeutic agents for the treatment of proliferating cells such as PSMA-expressing cancer cells, particularly PSMA-expressing prostate cancer cells. According to the invention, they are referred to as "metal complexes" or "radiopharmaceuticals".

[0121] Preferred imaging methods are positron emission tomography (PET) or single photon emission computed tomography (SPECT).

[0122] Preferably, at least one radionuclide is 89 Zr, 44 Sc, 111 In,90 Y, 66 Ga, 67 Ga, 68 Ga, 177 Lu, 99m Tc, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 66 Cu, 67 Cu, 149 Tb, 152 Tb, 155 Tb, 153 Sm, 161 Tb, 153 Gd, 155 Gd, 157 Gd, 213 Bi, 225 Ac, 230 U, 223 Ra, 165 Er, 52 Fe, 59 radioactive nuclides of Fe, and Pb (e.g., 203 Pb and 212 Pb, 211 Pb, 213 Pb, 214 Pb, 209 Pb, 198 Pb, 197 Pb) selected from the group consisting of.

[0123] More preferably, at least one radioactive nuclide is 90 Y, 68 Ga, 177 Lu, 225 Ac, and 213 Bi selected from the group consisting of. More preferably, the radioactive nuclide is 177 Lu or 225 Ac.

[0124] Preferably, the radionuclide has a half-life of at least 30 minutes, more preferably at least 1 hour, even more preferably at least 12 hours, still more preferably at least 1 day, and most preferably at least 5 days, and preferably, the radionuclide has a half-life of at most 1 year, more preferably at most 6 months, even more preferably at most 1 month, still more preferably at most 14 days. Thus, preferably, the radionuclide has a half-life of from 30 minutes to 1 year, more preferably from 12 hours to 6 months, still more preferably from 1 day to 1 month, and most preferably from 5 days to 14 days.

[0125] Preferably, the radionuclide is an α- and / or β-emitter, i.e., the radionuclide preferably emits α-particles (α-emitter) and / or β-radiation (β-emitter).

[0126] Preferably, when the radionuclide is an α-emitter, the α-particles have an energy of from 1 to 10 MeV, more preferably from 2 to 8 MeV, and most preferably from 4 to 7 MeV.

[0127] Preferably, when the radionuclide is a β-emitter, the β-radiation has an energy of from 0.1 to 10 MeV, more preferably from 0.25 to 5 MeV, and most preferably from 0.4 to 2 MeV.

[0128] Preferred radionuclides that emit β-radiation are 90 Y, 177 Lu, 59 Fe, 66 Cu, 67 Cu, 161 Tb, 153 Sm, 212 Pb, 211 Pb, 213 Pb, 214 Pb, 209 selected from the group consisting of Pb, and very preferred radionuclides that emit β-radiation are 177 Lu or 90 Y, most preferably 177 Lu. Preferably, in this case, the use is for diagnosis or treatment.

[0129] Preferred radionuclides that emit α-radiation are, for example, 213 Bi, 225 Ac, 149 Tb, 230 U and 223 Ra, 213 Bi, 230 selected from the group consisting of U, and more preferably, the radionuclide is 225 Ac and / or 213 Bi. A highly preferred radionuclide that emits α-radiation is, for example 225 Ac. Preferably, in this case, the use is for treatment.

[0130] According to a further embodiment, the radionuclide is a positron emitter. In this case, the radionuclide is preferably 89 Zr, 44 Sc, 66 Ga, 68 Ga and 64 selected from the group consisting of Cu. In this case, the use is preferably for PET diagnosis.

[0131] According to a more preferred embodiment, the radionuclide is a gamma emitter. In this case, the radionuclide is preferably 111 In, 67 Ga, 99m Tc, 155 Tb, 165 Er and 203 selected from the group consisting of Pb. In this case, the use is preferably for SPECT diagnosis.

[0132] According to a still more preferred embodiment, the radionuclide emits Auger electrons and preferably decays by electron capture. In this case, the radionuclide is preferably 67 Ga, 155 Tb, 153 Gd, 165 Er and 203 selected from the group consisting of Pb. In this case, the use is preferably for treatment.

[0133] Pharmaceutical composition As described above, the present invention also relates to a pharmaceutical composition comprising a PSMA binding ligand as described above or below or a complex as described above or below. The pharmaceutical composition should preferably be understood to comprise a therapeutically effective amount of each of the PSMA binding ligand and / or the complex. The pharmaceutical composition may further comprise at least one organic or inorganic solid or liquid and / or at least one pharmaceutically acceptable carrier.

[0134] The terms "medicine" and "pharmaceutical composition" as used herein relate to the PSMA binding ligand and / or complex of the present invention and optionally one or more pharmaceutically acceptable carriers, i.e., excipients. The PSMA binding ligand of the present invention can be formulated as a pharmaceutically acceptable salt, which is described above herein. The pharmaceutical composition is preferably administered locally (e.g., intratumorally), topically or systemically. Suitable routes of administration conventionally used for drug administration are oral, intravenous or parenteral administration, as well as inhalation. The preferred route of administration is parenteral administration. "Parenteral route of administration" means a mode of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, arterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, intratracheal, subcutaneous, subepidermal, intra-articular, subcapsular, intrathecal, intramedullary and intrasternal injections and infusions. Preferably, the administration is by intravenous administration or infusion. However, depending on the nature and mode of action of the PSMA binding ligand, the pharmaceutical composition may be administered by other routes as well.

[0135] Furthermore, the PSMA binding ligand can be administered in combination with other drugs either in a common pharmaceutical composition or as a separate pharmaceutical composition, where the separate pharmaceutical composition may be provided in the form of a kit of parts. The PSMA binding ligand is preferably administered in a conventional dosage form prepared by combining the drug with a standard pharmaceutical carrier according to conventional procedures. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate for the desired preparation. It is recognized that the form and characteristics of the pharmaceutically acceptable carrier or diluent are determined by the amount of active ingredient to be combined, the route of administration and other well-known variables.

[0136] An excipient must be compatible with the other ingredients of the formulation and, within the scope of sound medical judgment, be acceptable in the sense of having an appropriate benefit / risk ratio for use in contact with the patient's tissue without excessive toxicity, irritation, allergic response, or other problems or complications. Preferably, the excipient is not harmful to its recipient. The excipient used may be, for example, a solid, gel, or liquid carrier. Exemplary solid carriers are lactose, clay, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid, etc. Exemplary liquid carriers are phosphate buffered saline aqueous solution, syrup, oils such as peanut oil and olive oil, water, emulsions, various types of wetting agents, sterile solutions, etc. Similarly, the carrier or diluent may contain time-delay materials well known in the art, such as glyceryl monostearate or glyceryl distearate, alone or together with waxes. The suitable carriers include those described above and others well known in the art. See, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania. The diluent is selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, physiological saline, Ringer's solution, dextrose solution, and Hank's solution. In addition, the pharmaceutical composition or formulation may also contain other carriers, adjuvants, or non-toxic non-therapeutic non-immunogenic stabilizers, etc. When solutions for infusion or injection are used, they are preferably aqueous solutions or suspensions, which can be produced from lyophilized preparations containing, for example, the active substance as such or together with a carrier such as mannitol, lactose, glucose, albumin, etc., prior to use. The ready-made solutions are sterilized and, where appropriate, mixed with excipients such as preservatives, stabilizers, emulsifiers, solubilizers, buffers, and / or salts for adjusting the osmotic pressure. Sterilization can be obtained by sterile filtration using a filter with a small pore size, and, where appropriate, the composition can be lyophilized accordingly. A small amount of antibiotic can also be added to ensure the maintenance of sterility.

[0137] A therapeutically effective amount refers to the amount of a PSMA-binding ligand to be used in a pharmaceutical composition of the present invention for preventing, ameliorating, or treating symptoms associated with the diseases or conditions mentioned in this specification. The therapeutic efficacy and toxicity of such PSMA-binding ligands can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the therapeutically effective dose in 50% of the population) and LD50 (the lethal dose in 50% of the population). The dose ratio between the therapeutic and toxic effects is the therapeutic index, which can be expressed as the ratio of LD50 / ED50.

[0138] The dosing regimen is determined, preferably according to any one of the methods described above, by the attending physician and other clinical factors. As is well known in the medical art, the dosage for any one patient depends on many factors including the patient's size, body surface area, age, the particular PSMA binding ligand to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. Progression can be monitored by periodic assessments. Preferred dosages are specified below herein. Progression can be monitored by periodic assessments. The pharmaceutical compositions and formulations referred to herein are administered at least once to treat or prevent the diseases or conditions listed herein. However, said pharmaceutical compositions may be administered two or more times, for example 1 to 10 times. Preferably, the pharmaceutical compositions may be administered at a frequency of once every 1 to 6 months, more preferably once every 2 to 4 months. The particular pharmaceutical compositions are prepared in a manner well known in the pharmaceutical art and contain at least one active PSMA binding ligand as referred to above herein, in an additive mixture or otherwise in association with a pharmaceutically acceptable carrier or diluent. To prepare those particular pharmaceutical compositions, the active compounds are usually admixed with a carrier or diluent or enclosed or encapsulated in capsules, sachets, cachets, paper, or other suitable containers or vehicles. The resulting formulations should be adapted to the mode of administration, i.e., in the form of tablets, capsules, suppositories, solutions, suspensions, etc. Dosage recommendations are to be as indicated in the prescriber or user instructions to predict dosage adjustment depending on the recipient considered.

[0139] The term "patient" as used herein relates to vertebrates, preferably mammalian animals, more preferably humans, monkeys, female cattle, horses, cats or dogs. Preferably, the mammalian animal is a primate, more preferably a monkey, and most preferably a human.

[0140] The dosage of the PSMA-binding ligand administered to a patient is preferably defined as the compound dosage, i.e., the amount of the PSMA-binding ligand administered to the patient. A preferred diagnostic compound dosage is a total dosage of 1 to 10 nmol / patient, and thus, preferably, the diagnostic compound dosage is 0.02 to 0.1 nmol / kg body weight. A preferred therapeutic compound dosage is a total dosage of 10 to 100 nmol / patient, and thus, preferably, the therapeutic compound dosage is 0.2 to 1 nmol / kg body weight.

[0141] As will be understood by those skilled in the art, the dosage of the complex as specified herein, i.e., the complex comprising and preferably consisting of a radionuclide and a PSMA-binding ligand, is preferably expressed as the compound dosage as specified above, and the preferred dosage is the same as that specified above. More preferably, the dosage of the complex is expressed as the activity dosage, i.e., the amount of radioactivity administered to the patient. Preferably, the activity dosage is adjusted to avoid adverse effects as specified elsewhere herein. Preferably, the patient-specific dosage, preferably the patient-specific activity dosage, is determined taking into account the relevant factors as specified elsewhere herein, in particular, the treatment progression and / or adverse effects observed for each patient. Thus, preferably, the activity dosage is adjusted such that the organ-specific dosage in the salivary gland is at most 30 Sv, more preferably less than 20 Sv, even more preferably less than 10 Sv, and most preferably less than 5 Sv.

[0142] The effective amount may be administered once (single dose) at an activity dose of about 2 MBq to about 30 MBq, preferably 4 to 30 MBq, more preferably 6 to 30 MBq, more preferably 8 to 30 MBq, more preferably 10 to 30 MBq, more preferably 15 to 30 MBq, preferably 20 to 30 MBq per patient. Thus, the preferred therapeutic dose in such cases is 2 MBq to about 30 MBq / patient, preferably 4 to 30 MBq / patient, more preferably 6 to 30 MBq / patient, more preferably 8 to 30 MBq / patient, more preferably 10 to 30 MBq / patient, more preferably 15 to 30 MBq / patient, preferably 20 to 30 MBq / patient. Preferably, the activity dose is about 10 to 30 MBq per administration, for example, about 10 MBq, 11 MBq, 12 MBq, 13 MBq, 14 MBq, 15 MBq, 16 MBq, 17 MBq, 18 MBq, 19 MBq, 20 MBq, 21 MBq, 22 MBq, 23 MBq, 24 MBq, 25 MBq, 26 MBq, 27 MBq, 28 MBq, 29 MBq or 30 MBq, or any range between any two of the above values, etc. However, as specified hereinafter in this specification, higher or lower doses may be expected depending on the type and / or use of the radiation emitted by the radionuclide. The phrase "effective amount" or "therapeutically effective amount", as used herein, means the amount of a PSMA-binding ligand, a material or composition comprising a PSMA-binding ligand of the present invention, or other active ingredient that is effective to produce some desired therapeutic effect in the cells of at least a subpopulation of patients at a reasonable benefit / risk ratio applicable to any medical treatment. The therapeutically effective amount with respect to the PSMA-binding ligand of the present invention means the amount of the therapeutic agent that provides a therapeutic benefit in the treatment or prevention of a disease, alone or in combination with other treatments. The term used in connection with the PSMA-binding ligand of the present invention can include an amount that improves the overall treatment, reduces or avoids the symptoms or causes of the disease, or enhances the therapeutic effectiveness or synergistic effect with another therapeutic agent.

[0143] According to a preferred embodiment, the radionuclide is a β-emitter as specified above herein, more preferably177 It is Lu, and the use is for diagnosis. In such a case, the activity dosage of the complex is preferably at least 100 kBq / kg body weight, more preferably at least 500 kBq / kg body weight, and most preferably at least 1 MBq / kg body weight. More preferably, the radionuclide is a β-emitter as specified above herein, and more preferably 177 It is Lu, and the use is for treatment, preferably for the treatment of prostate cancer tumors as specified elsewhere herein. In such a case, the activity dosage of the complex is preferably at least 25 MBq / kg body weight, more preferably at least 50 MBq / kg body weight, and most preferably at least 80 MBq / kg body weight. Therefore, the preferred treatment dosage in such a case is 2 - 10 Gbq / patient, more preferably 4 - 8 GBq / patient, and most preferably about 6 GBq / patient.

[0144] More preferably, the radionuclide is an α-emitter as specified above herein, and more preferably 225 It is Ac, and the use is for treatment, preferably for the treatment of prostate cancer tumors as specified elsewhere herein. In such a case, the activity dosage of the complex is preferably in the range of 25 kBq / kg to about 500 kBq / kg of the patient's body weight. More preferably, the activity dosage of the complex is at least 75 kBq / kg body weight, more preferably at least 100 kBq / kg body weight, still more preferably at least 150 kBq / kg body weight, and most preferably at least 200 kBq / kg body weight. Therefore, preferably, in such a case, the activity dosage of the complex is 75 - 500 kBq / kg body weight, more preferably 100 - 400 kBq / kg body weight, still more preferably 150 - 350 kBq / kg body weight, and most preferably 200 - 300 kBq / kg body weight.

[0145] The present invention also relates to a PSMA-binding ligand as described above or below, a complex as described above or below, or a pharmaceutical composition as described above herein, for use in diagnosis, preferably for diagnosing a cell proliferative disease or disorder, in particular prostate cancer and / or its metastases. Further, the present invention also relates to a PSMA-binding ligand as described above or below, a complex as described above or below, or a pharmaceutical composition as described above or below, for use in medicine, preferably for treating or preventing a cell proliferative disease or disorder, in particular prostate cancer and / or its metastases.

[0146] As used herein, the term "diagnosing" refers to determining whether a subject has or does not have a disease or disorder, preferably a cell proliferative disease or disorder. As will be understood by those skilled in the art, such determination is preferably correct for 100% of the subjects being investigated, but usually may not be correct for 100% of the subjects being investigated. However, the term requires that a statistically significant proportion of the subjects be correctly determined and thus be diagnosable. Whether a portion is statistically significant can be readily determined by those skilled in the art using various well-known statistical evaluation tools, such as determination of confidence intervals, p-value determination, Student's t-test, Mann-Whitney test, etc. Details can be found in Dowdy and Wearden, Statistics for Research, John Wiley & Sons, New York 1983. Preferred confidence intervals are at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95%. The p-value is preferably 0.2, 0.1, or 0.05. As will be understood by those skilled in the art, diagnosing can include further diagnostic determinations, such as visual and / or manual examinations, determination of tumor biomarker concentrations in a sample of the subject, X-ray examinations, etc. The term includes not only the individual diagnosis of a patient, but also the continuous monitoring of a patient. Monitoring, i.e., diagnosing, the presence or absence of a cell proliferative disease or associated symptoms at various time points includes not only monitoring patients known to have a cell proliferative disease, but also monitoring subjects known to be at risk of developing a cell proliferative disease. Further, monitoring can also be used to determine whether a patient is being successfully treated or whether at least the symptoms of a cell proliferative disease can be improved over time by a particular treatment. Further, the term also includes classifying a subject according to a normal classification scheme, such as the T1-T4 staging known to those skilled in the art.

[0147] The terms "treating" and "treatment" refer to the amelioration of a disease or disorder referred to herein, or a symptom associated therewith, to a significant degree. The treating, as used herein, also includes the restoration of overall health with respect to the disease or disorder referred to herein. It should be understood that treating may not be effective in all subjects to be treated when the term is used herein. However, the term is preferably required to be such that a statistically significant proportion of subjects suffering from the disease or disorder referred to herein can be successfully treated. Whether a portion is statistically significant can be readily determined by one of ordinary skill in the art using various well-known statistical evaluation tools as specified above herein. The terms "preventing" and "prevention" refer to maintaining health in a subject for a particular time period with respect to the disease or disorder referred to herein. It is understood that the time period may be dependent on the amount of drug compound administered and the individual factors of the subject considered elsewhere in this specification. It should be understood that prevention may not be effective in all subjects treated with a PSMA binding ligand according to the invention. However, the term is preferably required to be such that a statistically significant proportion of a cohort or population of subjects is effectively prevented from suffering from the disease or disorder referred to herein, or a symptom associated therewith. Preferably, a cohort or population of subjects that would otherwise develop the disease or disorder referred to herein in the absence of the preventive measures according to the invention is contemplated in this context. Whether a portion is statistically significant can be readily determined by one of ordinary skill in the art using various well-known statistical evaluation tools as considered above herein.

[0148] Preferably, the treatment and / or prevention comprises administration of at least one PSMA binding ligand and / or at least one complex as specified elsewhere herein, more preferably at the active dosage and / or compound dosage as specified above.

[0149] As used herein, the term "proliferative cell disorder" relates to a disease in animals, including humans, characterized by uncontrolled growth by a population of somatic cells ("cancer cells"). This uncontrolled growth may be accompanied by invasion and destruction of the surrounding tissues by the cancer cells and possibly its spread (metastasis) to other locations in the body. Preferably, included thereon by the term cancer is recurrence. Thus, preferably, cancer is a solid tumor, metastasis, or its recurrence. Preferably, the proliferative cell disorder is an uncontrolled proliferation of cells, including cells that express PSMA.

[0150] Accordingly, preferably, the cell proliferative disease is a PSMA-expressing cancer. The term "PSMA-expressing cancer" refers to any cancer in which cancerous cells express prostate-specific membrane antigen (PSMA). Preferably, the cancer (or cancer cells) that can be treated according to the present invention is selected from prostate cancer, conventional renal cell cancer, transitional cell cancer of the bladder, lung cancer, testicular embryonal cancer, neuroendocrine cancer, colon cancer, brain tumor, and breast cancer, more preferably selected from PSMA-positive prostate cancer, PSMA-positive renal cell cancer, PSMA-positive transitional cell cancer of the bladder, PSMA-positive lung cancer, PSMA-positive testicular embryonal cancer, PSMA-positive neuroendocrine cancer, PSMA-positive colon cancer, PSMA-positive brain tumor, and PSMA-positive breast cancer. Whether a cancer is PSMA-positive can be determined by those skilled in the art by methods known in the art, for example, in vitro by immunostaining of cancer samples, or in vivo, for example, by PSMA scintigraphy, preferably both can be established as described by Kratochwil et al. (2017, J Nucl Med 58(10):1624). In a particularly preferred embodiment of the present invention, the PSMA-expressing cancer is prostate cancer or breast cancer, more preferably prostate cancer, even more preferably advanced-stage prostate cancer. Accordingly, preferably, the cell proliferative disease is prostate cancer stage T2, more preferably stage T3, most preferably stage T4. Preferably, the cell proliferative disease is metastatic prostate cancer, more preferably metastatic castration-resistant prostate cancer. Advantageously, administration of the PSMA-binding ligand and / or complex of the present invention to a patient results in an improved pharmacokinetic profile, particularly improved renal excretion, with essentially unchanged enrichment in the target tissue, preferably the cell proliferative tissue, more preferably the cancer tissue, as compared to, for example, PSMA-617 commonly used on the one hand, as shown in the studies underlying the present invention. The improved excretion can avoid and / or reduce the harmful side effects on non-target tissues, particularly the salivary gland and / or lacrimal gland. This is advantageous because harmful side effects on the salivary gland are considered as a dose-limiting factor (see Kratochwil et al. (2017, J Nucl Med 58(10):1624)).Based on the findings of the present invention, larger amounts of compounds and / or complexes, and in particular, higher doses of radioactivity, can be administered to a patient when compared to the compounds and complexes described in the art. Thus, the therapeutic window is wider than when using the compounds currently in use. Advantageously, moreover, the PSMA-binding ligands of the present invention provide an improved diagnosis, since co-labeling of non-related tissues and organs, in particular the salivary glands, lacrimal glands and / or kidneys, is reduced.

[0151] Accordingly, the PSMA-binding ligands and / or complexes of the present invention enable the treatment of PSMA-expressing cancers, in particular prostate cancer, and its metastases, and / or the diagnosis of PSMA-expressing cancers, in particular prostate cancer, and its metastases, and the PSMA-binding ligands and / or complexes exhibit an advantageous renal excretion profile, preferably with favorable clearance acceleration. Thus, the harmful side effects on the patient's kidneys are reduced. Accordingly, the present invention relates to a PSMA-binding ligand and / or complex, or a pharmaceutical composition as described above, for treating and / or preventing PSMA-expressing cancers, in particular prostate cancer and / or its metastases, in patients in need thereof, and also to a PSMA-binding ligand and / or complex, or a pharmaceutical composition, in cases where the subject suffers from renal insufficiency.

[0152] As detailed above and in the examples herein, the compounds as specified herein provide accelerated excretion while maintaining essentially the same enrichment in the target tissue as, for example, PSMA-617, and thus, the harmful effects on non-target tissues, preferably the salivary glands and / or lacrimal glands, are avoided or reduced. Thus, the treatments and / or diagnoses as specified herein have fewer or less severe harmful side effects on, for example, the salivary glands and / or lacrimal glands, or preferably, no harmful side effects, in particular on the salivary glands and / or lacrimal glands.

[0153] Preferably, the PSMA-binding ligands of the present invention enable the reduction and / or avoidance of adverse side effects, e.g., on the salivary and / or lacrimal glands, while maintaining substantially unchanged therapeutic efficacy. As will be appreciated by those skilled in the art in view of the above, the PSMA-binding ligands as specified herein preferably further enable the use of higher concentrations of the compound and / or higher doses of radioactivity without at least increasing the adverse effects, which may be particularly useful, for example, in diagnostic applications for detecting e.g. minimal metastases or small amounts of residual tumor tissue, and / or in therapy.

[0154] Accordingly, the PSMA-binding ligands and / or complexes of the present invention enable the treatment of PSMA-expressing cancers, particularly prostate cancer, and its metastases, and / or the diagnosis of PSMA-expressing cancers, particularly prostate cancer, and its metastases, in which xerostomia symptoms are avoided.

[0155] Preferably, the PSMA-binding ligands as described above or below, or the complexes as described above or below, or the pharmaceutical compositions as described above or below are used for in vivo imaging and radiotherapy. Suitable pharmaceutical compositions may contain a radiopharmaceutical agent or a radiotherapy agent having a radionuclide either as an element, i.e., radioactive iodine, or as a radioactive metal chelate complex of a PSMA-binding ligand in an amount sufficient for imaging, together with a pharmaceutically acceptable radiological vehicle. The radiological vehicle should be suitable for injection or aspiration and may be, for example, human serum albumin; buffered aqueous solutions such as buffers of tris(hydroxymethyl)-aminomethane (and its salts), phosphate buffer, citrate buffer, bicarbonate buffer, etc.; sterile water, physiological saline; and balanced ionic solutions containing chloride salts and / or dicarbonate salts, or normal plasma cations such as calcium, potassium, sodium and magnesium.

[0156] The concentration of the imaging agent or therapeutic agent in the radiological vehicle should be sufficient to provide satisfactory imaging. Appropriate dosages are described above herein. The imaging agent or therapeutic agent should be administered such that it remains in the patient for between about 1 hour and 10 days, although both longer and shorter time periods are acceptable. Thus, convenient ampoules containing 1 - 10 mL of an aqueous solution can be prepared.

[0157] Imaging can be performed in a manner known to those skilled in the art, for example, by injecting a sufficient amount of the imaging composition to provide appropriate imaging and then scanning with a suitable imaging or scanning machine, such as a tomography or gamma camera. In certain embodiments, a method of imaging a region in a patient comprises the steps of: (i) administering to the patient a diagnostically effective amount of a PSMA binding ligand complexed with a radionuclide, (ii) exposing the region of the patient to a scanning device, and (ii) obtaining an image of the region of the patient. In certain embodiments, the region to be imaged is the head or thorax. In other embodiments, the PSMA binding ligand and complex target the PSMA protein.

[0158] Accordingly, in some embodiments, there is provided a method of imaging a tissue, such as spleen tissue, kidney tissue, or PSMA-expressing tumor tissue, comprising contacting the tissue with a complex synthesized by contacting a radionuclide and a PSMA binding ligand as described above.

[0159] The amount of the PSMA binding ligand of the present invention, or a formulation comprising a complex or a salt, solvate, stereoisomer, or tautomer thereof, of the PSMA binding ligand, to be administered to a patient depends on several physiological factors. These factors, including the nature of the imaging to be performed, the tissue to be targeted for imaging or treatment, and the body weight and medical history of the patient to be imaged or treated using the radiopharmaceutical, are known to a physician.

[0160] Accordingly, in another aspect, the present invention provides a method of treating a patient suffering from a cell proliferative disease or disorder by administering to the patient a therapeutically effective amount of a complex as described above or below. Specifically, the cell proliferative diseases or disorders to be treated or imaged using the PSMA-binding ligand, pharmaceutical composition or radiopharmaceutical according to the present invention are, for example, cancers in the lung, liver, kidney, bone, brain, spinal cord, bladder, etc., such as prostate cancer and / or prostate cancer metastasis.

[0161] The PSMA-binding ligand of the present invention can be synthesized, for example, not only in solution but also on a solid phase using, for example, standard peptide coupling procedures, such as Fmoc solid-phase coupling procedures. Preferably, the chelating agent is coupled to the rest of the molecule in the last coupling step, followed by a deprotection step and, in the case of solid-phase chemistry, cleavage from the resin. However, other synthetic procedures are possible and are known to those skilled in the art. The preferred synthesis of the PSMA-binding ligand of the present invention is described in detail in the Examples section.

[0162] Summarizing the findings of the present invention, the following embodiments are preferred: 1. At least one neutral amino acid X, optionally N-alkylated 1 comprising at least one linker L AQ linked via a PSMA-binding motif Q and a chelating agent residue A, a PSMA-binding ligand or a pharmaceutically acceptable salt or solvate thereof, wherein X 1 is preferably Gly, Ala, βAla, Phe, aminohexanoic acid (Ahx = -NH-(CH 2 )) 5 -C(=O)-), and an amino acid containing at least one -(CH2-CH2-O)- group between the N-terminus and the C-terminus, more preferably X 1 is Gly, Ala, βAla, Phe, and the structure -NH-CH 2 -CH 2 -O-(CH2 -CH 2 -O) x1 -(CH2) y1 -C(=O)- (wherein x1 is an integer in the range of 0 to 15, y1 is 1 or 2), or X1 is Tyr, a PSMA-binding ligand or a pharmaceutically acceptable salt or solvate thereof. 2. The PSMA-binding ligand has structure (I) A-L AQ -Q (I) The PSMA-binding ligand according to embodiment 1, or a pharmaceutically acceptable salt or solvate thereof, having

[0163] 3. The PSMA-binding motif Q has the structure

[0164]

Chemical formula

[0165] 4. The PSMA-binding ligand according to any one of Embodiments 1 to 3, or a pharmaceutically acceptable salt or solvate thereof, which is a chelating agent residue derived from a chelating agent selected from the group consisting of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (=DOTA), N,N''-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N''-diacetic acid, 1,4,7-triazacyclononane-1,4,7-triacetic acid (=NOTA), 2-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl)pentanedioic acid (NODAGA), 2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1-yl)pentanedioic acid (DOTAGA), 1,4,7-triazacyclononane phosphinic acid (TRAP), 1,4,7-triazacyclononane phosphinic acid (TRAP), 1,4,7-triazacyclononane-1-[methyl(2-carboxyethyl)phosphinic acid]-4,7-bis[methyl(2-hydroxymethyl)phosphinic acid] (NOPO), 3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid (=PCTA), N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxysuccinamide (DFO), diethylenetriaminepentaacetic acid (DTPA), trans-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-DTPA), 1-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid (oxo-Do3A), p-isothiocyanatobenzyl-DTPA (SCN-Bz-DTPA), 1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M), 2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B), and 1-(2)-methyl-4-isocyanatobenzyl-DTPA (MX-DTPA).

[0166] 5. A consists of the group consisting of

[0167]

Chemical formula

[0168] 6. A is a structure

[0169]

Chemical formula

[0170] 7. The linker L AQ comprises at least one amino acid building block AS a wherein AS a has a structure

[0171]

Chemical formula

[0172] 8. The linker L AQ comprises at least one amino acid building block AS b wherein AS b has the structure (b)

[0173]

Chemical formula

[0174]

Chem.

[0175]

Chem.

[0176] 9. Linker L AQ is at least one amino acid building block AS a and at least one amino acid building block AS b including, wherein AS a has the structure

[0177]

Chem.

[0178]

Chem.

[0179] [Chemistry] and more preferably

[0180] [Chemistry] )(it is) The PSMA-binding ligand according to any one of Embodiments 1 to 6, or a pharmaceutically acceptable salt or solvate thereof, having

[0181] 10. The PSMA-binding ligand is of structure (Ia)

[0182] [Chemistry] (wherein R 1 is H or -CH 3 , preferably H, and R 2 , R 3 and R 4 are, independently of each other, -CO 2 H, -SO 2 H, -SO 3 H, -OSO 3 H, -PO 2 H, -PO 3 H and -OPO 3 H 2 selected from the group consisting of Q 1 is selected from the group consisting of alkylaryl, arylalkyl, aryl, alkylheteroaryl, heteroarylalkyl and heteroaryl Q 2 is selected from the group consisting of aryl, alkylaryl, arylalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl and alkylheteroaryl q is an integer from 0 to 3, and n1 is an integer in the range of 1 to 25) The PSMA-binding ligand according to any one of Embodiments 1 to 8, or a pharmaceutically acceptable salt or solvate thereof, having

[0183] 11. Q 1 is preferably a residue selected from the group consisting of naphthyl, phenyl, biphenyl, indolyl, benzothiazolyl, naphthylmethyl, phenylmethyl, biphenylmethyl, indolylmethyl and benzothiazolylmethyl, more preferably Q 1 is from the group

[0184]

Chemical formula

[0185]

Chemical formula

[0186] 12. R 3 , R 2 and R 4 is -CO 2 H, and R 1 is H, the PSMA-binding ligand according to any one of embodiments 10 or 11.

[0187] 13. Q 2 is

[0188]

Chemical formula

[0189]

Chemical formula

[0190] 14. The ligand has the structure

[0191] [Chemical formula] (wherein A is a chelating agent residue having a structure

[0192] [Chemical formula] and Q2 is Q2 is

[0193] [Chemical formula] and more preferably

[0194] [Chemical formula] and q is 1 q is 1 Q 1 is

[0195] [Chemical formula] and R 3 , R 2 and R 4 are -CO 2 H, R 1 is H, and n1 is an integer in the range of 1 to 25). The PSMA-binding ligand according to any one of Embodiments 1 to 13, having

[0196] 15. The PSMA-binding ligand according to any one of Embodiments 1 to 14, wherein X1 is selected from the group consisting of Gly, Ala, βAla, Phe, -NH-(CH 2 ) 5 -C(=O)-, and an amino acid containing at least one -(CH2-CH2-O)- group between the N-terminus and the C-terminus.

[0197] 16. The PSMA-binding ligand according to any one of Embodiments 1 to 14, wherein X1 is selected from the group consisting of Gly, Ala, βAla, Phe, -NH-(CH 2 ) 5-C(=O)-, and the structure -NH-CH 2 -CH 2 -O-(CH 2 -CH 2 -O) x1 -(CH2) y1 -C(=O)-(wherein x1 is an integer in the range of 0 to 15, and y1 is 1 or 2), and is selected from the group consisting of amino acid residues, the PSMA-binding ligand according to any one of Embodiments 1 to 14.

[0198] 17. The PSMA-binding ligand according to any one of Embodiments 1 to 16, wherein X1 is selected from the group consisting of Gly, Ala, βAla, and Phe.

[0199] 18. Linker L AQ comprises the constituent block (X1) n1 wherein X1 is selected from the group consisting of Gly, Ala, βAla, and Phe, or X1 is Tyr, and n1 is in the range of 2 to 20, preferably 3 to 15, more preferably 3, 5, 10, or 15, the PSMA-binding ligand according to any one of Embodiments 1 or 14.

[0200] 19. The PSMA-binding ligand according to any one of Embodiments 18, wherein n1 is 3.

[0201] 20. The PSMA-binding ligand according to any one of Embodiments 18, wherein n1 is 5.

[0202] 21. The PSMA-binding ligand according to any one of Embodiments 18, wherein n1 is 10.

[0203] 22. The PSMA-binding ligand according to any one of Embodiments 18, wherein n1 is 15.

[0204] 23. The PSMA-binding ligand according to any one of Embodiments 18 to 22, wherein X1 is Gly.

[0205] 24. The PSMA-binding ligand according to any one of embodiments 18 to 22, wherein X1 is Ala.

[0206] 25. The PSMA-binding ligand according to any one of embodiments 18 to 22, wherein X1 is βAla.

[0207] 26. The PSMA-binding ligand according to any one of embodiments 18 to 22, wherein X1 is Phe.

[0208] 27. Linker L AQ comprises the building block (X1) n1 wherein X1 has the structure -NH-CH 2 -CH 2 -O-(CH 2 -CH 2 -O) x1 -(CH2) y1 -C(=O)-(wherein the integer x1 ranges from 0 to 15 and y1 is 1 or 2), and n1 is 1, the PSMA-binding ligand according to embodiment 1 or 16.

[0209] 28. The PSMA-binding ligand according to embodiment 27, wherein the integer x1 is 1, 3, 5 or 7.

[0210] 29. The PSMA-binding ligand according to embodiment 27, wherein the integer x1 is 1 and y1 is 1.

[0211] 30. The PSMA-binding ligand according to embodiment 27, wherein the integer x1 is 3 and y1 is 2.

[0212] 31. The PSMA-binding ligand according to embodiment 27, wherein the integer x1 is 5 and y1 is 2.

[0213] 32. The PSMA-binding ligand according to embodiment 27, wherein the integer x1 is 7 and y1 is 2.

[0214] 33. Linker L AQ comprises the building block (X1) n1comprising, wherein X1 is -NH-(CH 2 ) 5 -C(=O)-, and n1 ranges from 2 to 20, preferably from 1 to 4, the PSMA-binding ligand according to any one of embodiments 1 or 14.

[0215] 34. The PSMA-binding ligand according to any one of embodiments 33, wherein n1 is 1.

[0216] 35. The PSMA-binding ligand according to any one of embodiments 33, wherein n1 is 2.

[0217] 36. The PSMA-binding ligand according to any one of embodiments 33, wherein n1 is 3.

[0218] 37. The PSMA-binding ligand according to any one of embodiments 33, wherein n1 is 3.

[0219] 38. The PSMA-binding ligand according to any one of embodiments 1 to 37, wherein the ligand has a structure as shown in FIG. 1, FIG. 2, FIG. 3, FIG. 4, FIG. 5, FIG. 6, FIG. 7, FIG. 8, FIG. 9, FIG. 10, FIG. 11, FIG. 12, FIG. 13, FIG. 14, FIG. 15, FIG. 16, FIG. 17, FIG. 18, FIG. 19, FIG. 20, FIG. 21 or FIG. 22.

[0220] 39. (a) a radionuclide, and (b) a PSMA-binding ligand according to any one of embodiments 1 to 37 or a pharmaceutically acceptable salt or solvate thereof comprising a complex.

[0221] 40. The radionuclide is 89 Zr, 44 Sc, 111 In, 90 Y, 66 Ga, 67 Ga, 68 Ga, 177 Lu, 99m Tc, 60 Cu, 61 Cu, 62 Cu,64 Cu, 66 Cu, 67 Cu, 149 Tb, 152 Tb, 155 Tb, 153 Sm, 161 Tb, 153 Gd, 155 Gd, 157 Gd, 213 Bi, 225 Ac, 230 U, 223 Ra, 165 Er, 52 Fe, 59 radionuclides of Fe, and Pb (e.g., 203 Pb and 212 Pb, 211 Pb, 213 Pb, 214 Pb, 209 Pb, 198 Pb, 197 Pb) selected from the group consisting of, more preferably 90 Y, 68 Ga, 177 Lu, 225 Ac, and 213 Bi selected from the group consisting of, more preferably, the radionuclide is 177 Lu or 225 Ac, the complex according to embodiment 39.

[0222] 41. A pharmaceutical composition comprising the PSMA-binding ligand according to any one of embodiments 1 to 38 or the complex according to embodiment 39 or 40.

[0223] 42. The PSMA-binding ligand according to any one of embodiments 1 to 38, or the complex according to embodiment 39 or 40, or the pharmaceutical composition according to embodiment 41, for use in medicine, preferably for treating and / or preventing PSMA-expressing cancer, particularly prostate cancer and / or its metastases.

[0224] 43. The PSMA-binding ligand according to any one of Embodiments 1 to 38, or the complex according to Embodiment 39 or 40, or the pharmaceutical composition according to Embodiment 41, for use in diagnostics.

[0225] 44. The PSMA-binding ligand according to any one of Embodiments 1 to 38, or the complex according to Embodiment 39 or 40, or the pharmaceutical composition according to Embodiment 41, for use in the diagnosis of cancer, preferably PSMA-expressing cancer, particularly prostate cancer and / or its metastases.

[0226] 45. The radionuclide is a β-emitter, more preferably 177 Lu, and preferably, the active dosage of the complex is at least 100 kBq / kg body weight, more preferably at least 500 kBq / kg body weight, and most preferably at least 1 MBq / kg body weight, for the PSMA-binding ligand, complex, or pharmaceutical composition for the use according to Embodiment 43 or 44.

[0227] 46. The radionuclide is an α-emitter, more preferably 225 Ac, and preferably, the active dosage of the complex is at least 75 kBq / kg body weight, more preferably at least 100 kBq / kg body weight, for the PSMA-binding ligand, complex, or pharmaceutical composition for the use according to Embodiment 42.

[0228] 47. The PSMA-binding ligand according to any one of Embodiments 18 to 22, wherein X1 is Tyr.

[0229] 48. The linker L AQ comprises the building block (X 1 ), n1 -X is selected from the group consisting of Gly, Ala, βAla and Phe, n1 is in the range of 2 to 20, preferably 3 to 15, more preferably 3, 5, 10 or 15, or -X 1 has the structure -NH-CH 2 -CH 2 -CH2 -O-(CH 2 -CH 2 -O) x1 -(CH2) y1 -C(=O)-(wherein the integer x1 ranges from 0 to 15 and y1 is 1 or 2), and n1 is 1 or - X 1 has the structure -NH-(CH 2 ) 5 -C(=O)-, and n1 ranges from 1 to 20, preferably from 1 to 4, or - X1 is Tyr, and n1 ranges from 2 to 20, preferably from 3 to 15, more preferably 3, 5, 10 or 15, The PSMA-binding ligand according to any one of claims 1 to 8.

[0230] All references cited throughout this specification are incorporated herein by reference in their entirety, not only with respect to the specifically recited disclosure content.

Examples

[0231] All commercially available chemicals were of analytical grade and used without further purification. 68 Ga (half-life 68 minutes) was 68 obtained from a Ge / 68 Ga generator (Galliapharm® Ge-68 / Ga-68 Generator, Eckert & Ziegler), and 177 Lu (half-life 6.6 days) was purchased from ITG. Compounds were purified using semi-preparative reverse-phase high-performance liquid chromatography (RP-HPLC; Chromolith Semi Prep RP-18e, 100×10 mm; Merck, Darmstadt, Germany). Compound analysis was performed using analytical RP-HPLC (RP-HPLC; Chromolith RP-18e, 100×4.6 mm; Merck, Darmstadt, Germany). Analytical HPLC runs were at 2 mL / min with a linear gradient over 10 minutes (from 5% A (0.1% aqueous TFA) to 100% B (CH 3It was carried out using 0.1% TFA in CN. The Agilent Technologies 1200 series system was equipped with variable UV and gamma detectors (Ramona*, Elysia). The UV absorbance was measured at 220 and 280 nm, respectively. For mass spectrometry, MALDI-MS (Daltonics Microflex, Bruker Daltonics, Bremen, Germany) was used.

[0232] DOTA-Gly x -Chx-2-NaI-PSMA, DOTA-Ala x -Chx-2-NaI-PSMA, DOTA-βAla x Synthesis of -Chx-2-NaI-PSMA (x = 3, 5, 10, 15) (「PSMA」 = 「Lys-urea-Glu」) The synthesis of the pharmacophore Glu-urea-Lys was carried out as described previously (1). Briefly, the synthesis started with the formation of isocyanate of the glutamyl moiety using triphosgene. Resin immobilized (2-chloro-trityl resin, Merck, Darmstadt) ε-allyloxycarbonyl protected lysine was added and reacted for 16 hours with gentle stirring. The resin was filtered off, and the allyloxy protecting group was removed by reacting twice with Pd(PPh 3 ) 4 (0.3 equivalent) and morpholine (15 equivalents).

[0233] Subsequently, a linker between the PSMA pharmacophore and the chelating agent was introduced by a standard Fmoc solid-phase protocol. In the first step, Fmoc-2-NaI-OH and N-Fmoc-transamic acid (5 equivalents each) were coupled in DMF using HATU (5 equivalents) and DIPEA (10 equivalents). Each coupling step was repeated once. Depending on the amino acid sequence, Fmoc-Gly-OH / Fmoc-Ala-OH or Fmoc-β-Ala-OH (5 equivalents / coupling) was coupled in DMF using HATU (5 equivalents) and DIPEA (10 equivalents) 3, 5, 10, and 15 times, respectively. Each coupling step was repeated once.

[0234] Thereafter, tris(tBu)DOTA (tris(tBu)-ester of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) (4 equivalents) was coupled in DMF using HATU (4 equivalents) and DIPEA (10 equivalents). The product was cleaved from the resin using TFA / TIPS / H 2 O (95 / 2.5 / 2.5, v / v / v) at room temperature for 3 hours and identified by mass spectrometry.

[0235]

Table 2

[0236] DOTA-Phe y -Chx-2-NaI-Lys-urea-Glu (y = 3, 5) and DOTA-Tyr y -Chx-2-NaI-Lys-urea-Glu (y = 3, 5) synthesis The synthesis of the pharmacophore Glu-urea-Lys was carried out as previously described (1). Briefly, the synthesis started with the formation of isocyanate of the glutamyl moiety using triphosgene. Resin-immobilized (2-chloro-trityl resin, Merck, Darmstadt) ε-allyloxycarbonyl-protected lysine was added and reacted for 16 hours with gentle stirring. The resin was filtered off, and the allyloxy protecting group was removed under ambient conditions (1 hour, room temperature) using Pd(PPh3 ) 4 It was removed by reacting twice with (0.3 equivalent) and morpholine (15 equivalents).

[0237] Subsequently, a linker between the PSMA pharmacophore and the chelating agent was introduced by a standard Fmoc solid-phase protocol. In the first step, Fmoc-2-NaI-OH and N-Fmoc-transamic acid (5 equivalents each) were coupled in DMF using HATU (5 equivalents) and DIPEA (10 equivalents). Each coupling step was repeated once. Depending on the amino acid sequence, Fmoc-Phe-OH (5 equivalents / coupling) or Fmoc-Tyr(tBu)-OH was coupled 3 times or 5 times respectively in DMF using HATU (5 equivalents) and DIPEA (10 equivalents). Each coupling step was repeated once.

[0238] Thereafter, tris(tBu)DOTA (tris(tBu)-ester of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) (4 equivalents) was coupled in DMF using HATU (4 equivalents) and DIPEA (10 equivalents). The product was cleaved from the resin at room temperature for 3 hours using TFA / TIPS / H 2 O (95 / 2.5 / 2.5, v / v / v) and identified by mass spectrometry.

[0239]

Table 3

[0240] PSMA-NaI-Chx-Ahx z -DOTA (z = 1, 2, 3, 4) Synthesis The synthesis of the pharmacophore Glu-urea-Lys was carried out as described previously (1). Briefly, the synthesis was initiated with the formation of isocyanate of the glutamyl moiety using triphosgene. Resin-immobilized (2-chloro-trityl resin, Merck, Darmstadt) ε-allyloxycarbonyl-protected lysine was added and reacted for 16 h with gentle stirring. The resin was filtered off, and the allyloxy protecting group was removed by reacting twice with Pd(PPh 3 ) 4 (0.3 equiv) and morpholine (15 equiv) at ambient conditions (1 h, room temperature).

[0241] Subsequently, a linker between the PSMA pharmacophore and the chelator was introduced by a standard Fmoc solid-phase protocol. In the first step, Fmoc-2-NaI-OH and N-Fmoc-transamic acid (5 equiv each) were coupled in DMF using HATU (5 equiv) and DIPEA (10 equiv). Each coupling step was repeated once. Depending on the amino acid sequence, 6-(Fmoc-amino)-hexanoic acid (5 equiv / coupling) was coupled in DMF using HATU (5 equiv) and DIPEA (10 equiv) one, two, three, or four times, respectively. Each coupling step was repeated once.

[0242] Thereafter, tris(tBu)DOTA (tris(tBu)-ester of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) (4 equiv) was coupled in DMF using HATU (4 equiv) and DIPEA (10 equiv). The product was cleaved from the resin at room temperature for 3 h using TFA / TIPS / H 2 O (95 / 2.5 / 2.5, v / v / v) and identified by mass spectrometry.

[0243]

Table 4

[0244] Synthesis of DOTA-PEG2-Chx-2-NaI-Lys-urea-Glu, DOTA-PEG4-Chx-2-NaI-Lys-urea-Glu, DOTA-PEG6-Chx-2-NaI-Lys-urea-Glu, DOTA-PEG8-Chx-2-NaI-Lys-urea-Glu The synthesis of the pharmacophore Glu-urea-Lys was carried out as described previously (1). Briefly, the synthesis was initiated by the formation of isocyanate of the glutamyl moiety using triphosgene. Resin-immobilized (2-chlorotrityl resin, Merck, Darmstadt) ε-allyloxycarbonyl-protected lysine was added and reacted for 16 h with gentle stirring. The resin was filtered off, and the allyloxy protecting group was removed by reacting twice with Pd(PPh 3 ) 4 (0.3 equiv) and morpholine (15 equiv) at ambient conditions (1 h, room temperature).

[0245] Subsequently, a linker between the PSMA pharmacophore and the chelator was introduced by a standard Fmoc solid-phase protocol. In the first step, Fmoc-2-NaI-OH and N-Fmoc-transamic acid (4 equiv each) were coupled in DMF using HATU (4 equiv) and DIPEA (10 equiv).

[0246] Depending on the amino acid sequence, Fmoc-8-amino-3,6-dioxaoctanoic acid (5 equiv) or Fmoc-15-amino-4,7,10,13-tetraoxapentadecanoic acid (5 equiv) or Fmoc-21-amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid (5 equiv) or Fmoc-27-amino-4,7,10,13,16,19-22-25-octaoxaheptacosanic acid (5 equiv) was coupled in DMF using HATU (5 equiv) and DIPEA (10 equiv) respectively. Each coupling step was repeated once for each peptide using the individual PEG reactant.

[0247] Thereafter, tris(tBu)DOTA (tris(tBu)-ester of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) (3 equivalents) was coupled in DMF using HATU (3 equivalents) and DIPEA (10 equivalents). The DOTA coupling was also repeated once for each peptide. The product was cleaved from the resin using TFA / TIPS / H 2 O (95 / 2.5 / 2.5, v / v / v) at room temperature for 3 hours and identified by mass spectrometry.

[0248]

Table 5

[0249] In vitro property evaluation 177 Lu labeling The precursor peptide [2 nmol in HEPES buffer (0.1 M, pH 7, 50 μL)] was added to 10 μL 177 Lu]LuCl 3 (approx. 10 - 30 MBq, 0.04 M HCl). The reaction mixture was incubated at 95 °C for 15 minutes. The radiochemical yield (RCY) was determined by RP-HPLC.

[0250] Cell culture PSMA + LNCaP cells (CRL-1740; ATCC; PSMA positive) were cultured in RPMI medium supplemented with 10% fetal bovine serum and 2 mmol / L L-glutamine (all from PAA). The cells were grown in humidified air containing 5% CO 2 at 37 °C and harvested using trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA; 0.25% trypsin, 0.02% EDTA, Invitrogen).

[0251] Cell binding and internalization The internalization experiment was performed as described previously (2).

[0252] For the internalization experiment, 10 per well were seeded 24 hours prior to incubation5 Individual cells were seeded in a poly-L-lysine-coated 24-well cell culture plate. After washing, the cells were incubated with 30 nM of radiolabeled DOTA compound at 37 °C for 45 minutes (labeling was performed using 5 nmol of precursor peptide). Specific cell uptake was determined by blockade using 500 μM 2-PMPA (2-(phosphonomethyl)pentanedioic acid). Cell uptake was terminated by washing 3 times with 1 mL of ice-cold PBS. To remove surface-bound radioactivity, the cells were incubated twice for 5 minutes with glycine-HCl (50 mM, pH = 2.8) in 0.5 mL of PBS. The cells were washed with 1 mL of ice-cold PBS and lysed using 0.3 N NaOH (0.5 mL). The surface-bound and internalized fractions were measured with a gamma counter. Cell uptake was calculated as the percentage [%ID / 10 5 of the initially added radioactivity bound to 10 5 cells].

[0253]

Table 6

[0254] References TIFF2025516759000052.tif60169

Claims

1. at least one neutral amino acid X 1 at least one linker L including AQ A PSMA-binding ligand or a pharmaceutically acceptable salt or solvate thereof, comprising a PSMA-binding motif Q and a chelating agent residue A linked via a .

2. The PSMA-binding ligand according to Claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein X1 is selected from the group consisting of Gly, Ala, βAla, Phe, aminohexanoic acid (-NH-(CH2)5-C(=O)-), and amino acids having at least one -(CH2-CH2-O)- group between the N-terminus and C-terminus.

3. The PSMA-binding ligand according to Claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein X1 is selected from the group consisting of Gly, Ala, βAla, Phe, and amino acid residues having the structure -NH-CH2-CH2-O-(CH2-CH2-O)x1-(CH2)y1-C(=O)- (wherein x1 is an integer in the range of 0 to 15, and y1 is 1 or 2).

4. The PSMA-binding ligand has structure (I). A-L AQ -Q (I) A PSMA-binding ligand according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, having the above.

5. The PSMA-binding motif Q has a structure 【Chemistry 1】 (wherein, R 1 is H or -CH3, and R 2 , R 3 and R 4 are each independently selected from the group consisting of -CO 2 H, -SO 2 H, -SO 3 H, -OSO 3 H, -PO 2 H, -PO 3 H and -OPO 3 H 2 ). A PSMA-binding ligand according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, having the above.

6. A is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (=DOTA), N,N''-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N''-diacetic acid, 1,4,7-triazacyclononane-1,4,7-triacetic acid (=NOTA), 2-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl)pentanedioic acid (NODAGA), 2-(4,7,10-tris(carboxymethyl)-1,4,7, 10-Tetraazacyclododecane-1-yl)pentanedioic acid (DOTAGA), 1,4,7-Triazacyclononanephosphinic acid (TRAP), 1,4,7-Triazacyclononanephosphinic acid (TRAP), 1,4,7-Triazacyclononane-1-[methyl(2-carboxyethyl)phosphinic acid]-4,7-bis[methyl(2-hydroxymethyl)phosphinic acid](NOPO), 3,6,9,15-Tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene -3,6,9-triacetic acid (=PCTA), N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxysuccinamide (DFO), diethylenetriaminepentaacetic acid (DTPA), trans-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-DTPA), 1-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid (oxo-Do 3A) A PSMA-binding ligand according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, which is a chelating agent residue derived from a chelating agent selected from the group consisting of p-isothiocyanatobenzyl-DTPA (SCN-Bz-DTPA), 1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M), 2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B), and 1-(2)-methyl-4-isocyanatobenzyl-DTPA (MX-DTPA).

7. A is a group consisting of the following 【Chemistry 2】 A PSMA-binding ligand according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, which is a chelating agent residue having a structure selected from the above.

8. A is structure 【Transformation 3】 A PSMA-binding ligand according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, which is a chelating agent residue having the chelating agent residue.

9. Linker L AQ However, at least one amino acid constituent block AS a Includes AS a However, structure 【Chemistry 4】 (In the formula, Q 1 (Selected from the group consisting of alkylaryl, arylalkyl, aryl, alkylheteroaryl, heteroarylalkyl, and heteroaryl) A PSMA-binding ligand according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, having the above.

10. Linker L AQ However, at least one amino acid constituent block AS b Includes AS b However, structure (b) 【Transformation 5】 (In the formula, Q 2 is selected from the group consisting of aryl, alkylaryl, arylalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl and alkylheteroaryl, or Q2 is, 【Transformation 6】 is, or Q2 is, 【Transformation 7】 (is) A PSMA-binding ligand according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, having the above.

11. The PSMA-binding ligand has structure (Ia). 【Transformation 8】 (In the formula, R 1 is H or -CH3, and R 2 , R 3 and R 4 They are, independently of each other, -CO 2 H, -SO 2 H, -SO 3 H, -OSO 3 H, -PO 2 H, -PO 3 H and -OPO 3 H 2 Selected from the group consisting of, Q 1 This is selected from the group consisting of alkylaryl, arylalkyl, aryl, alkylheteroaryl, heteroarylalkyl, and heteroaryl. Q 2 This is selected from the group consisting of aryl, alkylaryl, arylalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, and alkylheteroaryl. (where q is an integer between 0 and 3, and n1 is an integer between 1 and 25) A PSMA-binding ligand according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, having the above.

12. Linker L AQ However, the constituent block (X 1 ) n1 Includes, - X 1 However, it is selected from the group consisting of Gly, Ala, βAla, and Phe, and n1 is in the range of 2 to 20, or - X 1 However, the structure -NH-CH 2 -CH 2 -O-(CH 2 -CH 2 -O) x1 -(CH2) y1 -C(=O)- (wherein integer x1 is in the range of 0 to 15, and y1 is 1 or 2), and n1 is 1 or - X 1 However, the structure -NH-(CH 2 ) 5 It has -C(=O)- and n1 is in the range of 1 to 20, or - X1 is Tyr, and n1 is in the range of 2 to 20. The PSMA-binding ligand according to claim 1.

13. (c) Radionuclides, and (d) PSMA-binding ligand according to any one of claims 1 to 12 or a pharmaceutically acceptable salt or solvate thereof A complex containing [a certain component].

14. Radioactive nuclides, 89 Zr, 44 Sc, 111 In, 90 Y, 66 Ga, 67 Ga, 68 Ga, 177 Lu, 99m Tc, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 66 Cu, 67 Cu, 149 Tb, 152 Tb, 155 Tb, 153 Sm, 161 Tb, 153 Gd, 155 Gd, 157 Gd, 213 Bi, 225 Ac, 230 U, 223 Ra, 165 Er, 52 Fe, 59 Radioactive nuclides of Fe and Pb (for example, 203 Pb and 212 Pb, 211 Pb, 213 Pb, 214 Pb, 209 Pb, 198 Pb, 197 The complex according to claim 13, selected from the group consisting of Pb).

15. A pharmaceutical composition comprising a PSMA-binding ligand according to any one of claims 1 to 12, or a pharmaceutically acceptable salt or solvate thereof.

16. A pharmaceutical composition according to claim 15, preferably for medical use, to treat and / or prevent PSMA-expressing cancer, particularly prostate cancer and / or its metastases.

17. A pharmaceutical composition according to claim 15 for use in diagnostics.

18. The pharmaceutical composition according to claim 15 for use in the diagnosis of cancer, preferably PSMA-expressing cancer, particularly prostate cancer and / or its metastases.

19. A pharmaceutical composition comprising the complex described in Claim 13.

20. A pharmaceutical composition according to claim 19, for use in diagnostics, preferably for cancer, more preferably for use in the diagnosis of PSMA-expressing cancer, particularly prostate cancer and / or its metastasis, wherein the radionuclide is a β-emitter, and the active dose of the complex is at least 100 kBq / kg body weight.

21. A pharmaceutical composition according to claim 19, for use in medicine, preferably for treating and / or preventing PSMA-expressing cancer, particularly prostate cancer and / or its metastases, wherein the radionuclide is an α-emitter, and preferably the active dose of the complex is 75 kBq / kg body weight.

Images